Il ruolo della sperimentazione clinica nel processo di sviluppo del farmaco: l'effetto "Arrow" e la competizione tecnologica

Journal title STUDI ECONOMICI
Author/s Laura Ferrari Bravo
Publishing Year 1 Issue 2002/77
Language Italian Pages 12 P. File size 165 KB
DOI
DOI is like a bar code for intellectual property: to have more infomation click here

Below, you can see the article first page

If you want to buy this article in PDF format, you can do it, following the instructions to buy download credits

Article preview

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

The economic literature on sequential innovations acknowledges that the successful firm earns a monopoly position only until the next innovation arrives. Such a dynamic process - which Schumpeter (1942, p. 83) labeled "creative destruction" - implies that leadership on the market by one firm is only a matter of time, since a new innovating firm will sooner or later displace the former incumbent. In the pharmaceutical industry, this sort of reasoning, which connects to the so-called Arrow effect, conflicts with empirical evidence on leading companies experiencing long lasting high market shares. Since these companies operate at the leading edge of technology by accounting for most of the research done, we believe that at least for the pharmaceutical industry there are elements of the R&D process neglected by the literature on innovation which may question the validity of the Arrow effect. We therefore model the behavior of pharmaceutical firm by introducing the role of clinical trials in shaping R&D decisions.

Laura Ferrari Bravo, Il ruolo della sperimentazione clinica nel processo di sviluppo del farmaco: l'effetto "Arrow" e la competizione tecnologica in "STUDI ECONOMICI " 77/2002, pp , DOI: